par de Azambuja, Evandro ;Bedard, Philippe L;Suter, T.;Piccart-Gebhart, Martine
Référence Targeted oncology, 4, 2, page (77-88)
Publication Publié, 2009-04
Référence Targeted oncology, 4, 2, page (77-88)
Publication Publié, 2009-04
Article révisé par les pairs
Titre: |
|
Auteur: | de Azambuja, Evandro; Bedard, Philippe L; Suter, T.; Piccart-Gebhart, Martine |
Informations sur la publication: | Targeted oncology, 4, 2, page (77-88) |
Statut de publication: | Publié, 2009-04 |
Sujet CREF: | Sciences bio-médicales et agricoles |
Mots-clés: | Anti-HER-2 therapies |
Breast cancer | |
Cardiotoxicity | |
Lapatinib | |
Trastuzumab | |
MeSH keywords: | Adjuvants, Immunologic -- administration & dosage |
Anthracyclines -- administration & dosage | |
Antibodies, Monoclonal -- administration & dosage | |
Antibodies, Monoclonal -- adverse effects | |
Breast Neoplasms -- immunology | |
Breast Neoplasms -- mortality | |
Breast Neoplasms -- pathology | |
Breast Neoplasms -- physiopathology | |
Breast Neoplasms -- therapy | |
Drug Resistance, Neoplasm | |
Female | |
Heart Failure -- chemically induced | |
Humans | |
Oxidative Stress | |
Protein Kinase Inhibitors -- administration & dosage | |
Protein Kinase Inhibitors -- adverse effects | |
Quinazolines -- administration & dosage | |
Quinazolines -- adverse effects | |
Receptor, Epidermal Growth Factor -- antagonists & inhibitors | |
Receptor, erbB-2 -- antagonists & inhibitors | |
Receptor, erbB-2 -- immunology | |
Survival Rate | |
Ventricular Outflow Obstruction -- chemically induced | |
Note générale: | Journal Article |
Review | |
Langue: | Anglais |
Identificateurs: | urn:issn:1776-260X |
info:doi/10.1007/s11523-009-0112-2 | |
info:scp/67349248085 | |
info:pmid/19418111 |